Compare Crispr Therapeutics AG (CRSP) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Enphase Energy Inc — how do they compare? Crispr Therapeutics AG trades at $53.83 (market cap $5.23B), while Enphase Energy Inc trades at $40.92 (market cap $5.59B). The key difference: Crispr Therapeutics AG and Enphase Energy Inc are close in size by market cap. Which is the better fit depends on your goals.
| CRSP | ENPH | |
|---|---|---|
Market Cap | $5.23B | $5.59B |
Sector | Health | Technology |
52-Week High | $76.78 | $72.33 |
52-Week Low | $44.34 | $26.12 |
Enterprise Value | $3.65B | $5.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Enphase Energy (ENPH) trades at $41.06, up 0.34% with a bullish technical outlook supported by moving averages. The company reported mixed Q2 2026 earnings matching estimates but missing revenue expectations, with revenue declining 19.6% year-over-year. Recent developments include expanded battery system support and US manufacturing commitments. Valuation metrics show a P/E of 41.88 and P/S of 4.25, while profitability remains solid with 10.09% net income margin.
The stock presents recovery potential with analyst consensus target of $45.37 (10.5% upside), though faces headwinds from cyclical residential solar demand and competitive pressures. Key risks include execution challenges in European expansion and AI data center strategy, while institutional interest remains mixed with recent insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
